MCC NEET Round 3 counselling begins, deadline issued for candidates seeking nationality conversion to NRI

New Delhi- The Medical Counselling Committee (MCC) has issued a notice for candidates seeking admission under the NRI quota in the National Eligibility and Entrance Test-Undergraduate (NEET UG) Round-3 counselling…

Continue ReadingMCC NEET Round 3 counselling begins, deadline issued for candidates seeking nationality conversion to NRI

IGMCRI’s Nursing college Principal, Faculty under probe over caste abuse allegations by student

Puducherry- Alleging assault and caste-based abuse, a second-year nursing student has filed a complaint with the National Commission for Scheduled Castes and Scheduled Tribes. According to The New Indian Express report,…

Continue ReadingIGMCRI’s Nursing college Principal, Faculty under probe over caste abuse allegations by student

Dr Reddy’s Labs appoints Gayatri Prabhu as Head Digital Marketing (Emerging Markets)

Hyderabad: Dr Reddy's Labs has appointed Gayatri Prabhu as Head Digital Marketing (Emerging Markets). Gayatri is a result-driven Digital Professional with 20 plus years of experience in driving Innovation, Digital Transformation and…

Continue ReadingDr Reddy’s Labs appoints Gayatri Prabhu as Head Digital Marketing (Emerging Markets)

Once-Weekly Semaglutide bests Sitagliptin for blood sugar, Weight, and Lipid Profile control in T2DM: Study

Hungary: Researchers have found in a new study that once-weekly semaglutide significantly reduces weight and HbA1c while favorably modifying atherogenic lipoprotein subfractions in type 2 diabetes patients. After 52 weeks,…

Continue ReadingOnce-Weekly Semaglutide bests Sitagliptin for blood sugar, Weight, and Lipid Profile control in T2DM: Study

Hormone Therapy for VMS: Safe in Women 50-59, Risky in Those 70+, Finds JAMA Study

USA: A secondary analysis of two randomized clinical trials found that conjugated equine estrogens (CEE) alone and CEE plus medroxyprogesterone acetate (MPA) reduced vasomotor symptoms (VMS) without raising ASCVD risk…

Continue ReadingHormone Therapy for VMS: Safe in Women 50-59, Risky in Those 70+, Finds JAMA Study